Biotech Values

[DewDiligence]

Copaxone was mentioned in passing on MYL’s 4Q10 CC today.* COO Heather Bresch confirmed that the 30-month Hatch-Waxman stay on MYL’s Paragraph-IV challenge runs out in Mar 2012. We already knew this date by simple arithmetic insofar as the FDA accepted MYL’s Copaxone ANDA for review in Sep 2009 (#msg-41441618), when MYL notified Teva of the Paragraph-IV challenge triggering the start of the 30-month clock.

MYL’s 4Q10 PR:
http://investor.mylan.com/releasedetail.cfm?ReleaseID=552326

MYL’s 4Q10 CC slides:
http://investor.mylan.com/common/download/download.cfm?companyid=ABEA-2LQZGT&fileid=443927&filekey=b7c8185d-6856-4463-8eba-e44efdc2b43e&filename=MYLAN%20Q4%202010%2002._24_2011.pdf

*The reference was so fleeting I missed it on the first listen.